ADMA Biologics sets 2025 executive comp; CEO Grossman base $925k with equity awards

ADMA BIOLOGICS, INC.

CEO Grossman: 2025 base $925k, 2024 cash bonus $1.02M, 252,022 RSUs, 376,744 options at $16.07 strike.
COO Kestenberg: 2025 base $575k, 2024 bonus $293,625, 77,784 RSUs, 116,279 options.
CFO Tade: 2025 base $500k, 2024 bonus $254,475, 62,227 RSUs, 93,023 options.
Non-employee directors get annual equity grants of $350k (50% RSUs, 50% options) and increased committee retainers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.